Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
3.56
Dollar change
-0.09
Percentage change
-2.47
%
Index- P/E- EPS (ttm)-0.73 Insider Own2.90% Shs Outstand49.70M Perf Week-1.93%
Market Cap176.97M Forward P/E7.91 EPS next Y0.45 Insider Trans0.00% Shs Float48.27M Perf Month-4.91%
Income-36.03M PEG- EPS next Q0.84 Inst Own1.28% Short Float0.20% Perf Quarter-5.07%
Sales30.92M P/S5.72 EPS this Y88.70% Inst Trans8.96% Short Ratio5.38 Perf Half Y8.87%
Book/sh1.62 P/B2.19 EPS next Y854.25% ROA-15.73% Short Interest0.10M Perf Year-9.41%
Cash/sh1.73 P/C2.06 EPS next 5Y- ROE-37.09% 52W Range2.89 - 4.75 Perf YTD-7.53%
Dividend Est.- P/FCF- EPS past 5Y- ROI-23.33% 52W High-25.05% Beta1.08
Dividend TTM- Quick Ratio2.95 Sales past 5Y13222.39% Gross Margin- 52W Low23.03% ATR (14)0.15
Dividend Ex-Date- Current Ratio2.95 EPS Y/Y TTM-164.11% Oper. Margin-133.82% RSI (14)46.56 Volatility2.83% 3.65%
Employees148 Debt/Eq1.02 Sales Y/Y TTM46.16% Profit Margin-116.52% Recom1.00 Target Price10.06
Option/ShortNo / Yes LT Debt/Eq0.92 EPS Q/Q- Payout- Rel Volume0.01 Prev Close3.65
Sales Surprise5.78% EPS Surprise-41.10% Sales Q/Q- EarningsNov 09 AMC Avg Volume18.39K Price3.56
SMA20-0.56% SMA50-3.03% SMA200-1.33% Trades Volume214 Change-2.47%
Date Action Analyst Rating Change Price Target Change
Dec-20-21Upgrade H.C. Wainwright Neutral → Buy $8
Jul-23-20Upgrade Stifel Hold → Buy
Jun-25-20Initiated BofA/Merrill Underperform $7
May-13-20Downgrade Kepler Buy → Reduce
May-12-20Downgrade H.C. Wainwright Buy → Neutral $46 → $11
May-12-20Downgrade Barclays Overweight → Equal Weight $55 → $14
Oct-29-19Reiterated B. Riley FBR Buy $52 → $43
Jun-25-19Initiated Stifel Hold
Apr-24-19Initiated SVB Leerink Outperform $58
Apr-22-19Initiated Barclays Overweight
Feb-29-24 04:10PM
Jan-15-24 04:10PM
Jan-11-24 04:10PM
Dec-08-23 01:55AM
Dec-07-23 05:15AM
11:30AM Loading…
Dec-06-23 11:30AM
Nov-16-23 04:10PM
Nov-13-23 04:30PM
Nov-09-23 04:10PM
Nov-02-23 05:10PM
Sep-26-23 04:10PM
Sep-20-23 04:10PM
Sep-05-23 04:10PM
Aug-10-23 04:10PM
Jul-12-23 04:10PM
01:00AM Loading…
Jun-30-23 01:00AM
Jun-07-23 04:10PM
May-31-23 04:44PM
04:10PM
May-24-23 01:00PM
May-23-23 04:10PM
May-11-23 04:10PM
May-09-23 04:10PM
Apr-27-23 04:10PM
Apr-19-23 04:10PM
Apr-18-23 04:10PM
Apr-13-23 04:10PM
Feb-28-23 04:10PM
Jan-30-23 04:10PM
Jan-24-23 04:10PM
04:10PM Loading…
Jan-05-23 04:10PM
Nov-17-22 04:10PM
Nov-10-22 04:10PM
Oct-25-22 04:10PM
Sep-29-22 04:10PM
Sep-28-22 04:10PM
Sep-19-22 12:42PM
01:30AM
Sep-13-22 04:10PM
Jul-08-22 04:10PM
11:12AM
May-25-22 04:10PM
May-11-22 04:10PM
Apr-29-22 04:10PM
Apr-20-22 04:10PM
Apr-14-22 12:00PM
Apr-07-22 04:10PM
Feb-28-22 04:10PM
Jan-24-22 04:10PM
Jan-21-22 04:10PM
Jan-11-22 10:00AM
Dec-23-21 10:00AM
Dec-17-21 11:42AM
06:25AM
01:15AM
01:00AM
01:00AM
Nov-18-21 04:15PM
Nov-09-21 04:10PM
Nov-08-21 04:10PM
Nov-02-21 05:10PM
Sep-29-21 04:10PM
Jul-09-21 04:10PM
Jun-30-21 04:10PM
Jun-24-21 04:10PM
Jun-23-21 04:10PM
Jun-18-21 12:52PM
Jun-15-21 04:10PM
May-27-21 04:10PM
May-12-21 04:10PM
May-11-21 04:10PM
May-10-21 04:10PM
May-03-21 02:10AM
Apr-23-21 12:30PM
Apr-22-21 04:10PM
Apr-01-21 04:10PM
Mar-04-21 04:10PM
Mar-01-21 04:05PM
Feb-26-21 04:10PM
Feb-23-21 10:50AM
Feb-22-21 04:10PM
Feb-18-21 05:00PM
Feb-12-21 05:00PM
Feb-10-21 04:10PM
12:16PM
07:34AM
06:42AM
Feb-09-21 04:10PM
Jan-28-21 04:10PM
Jan-27-21 03:30PM
Jan-25-21 01:30PM
Jan-13-21 04:15PM
04:10PM
Jan-12-21 02:15PM
Jan-11-21 04:10PM
Jan-08-21 12:30PM
Jan-06-21 04:10PM
Dec-23-20 03:11PM
02:00PM
12:00PM
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver. The company was founded by Jean-Francois Mouney, Florence Sejourne, and Bart Staels in September 1999 and is headquartered in Loos, France.